Despite intact 2025 EBITDA margin guidance, a soft Q1 and near-term uncertainties made us cut our 2025–2027e EPS by c10%. The step-up of focus on regulated markets supports the long-term case, although it comes with costs near-term. We reiterate our BUY but have cut our target price to SEK1,100 (1,440). We expect buybacks, expansion, new games, and growth improvements to strengthen the story later in 2025.
Arctic Bioscience announced 52-week results for the HeROPA trial (mild to moderate psoriasis). The results did not include detailed data and only a very limited number of the predefined secondary endpoints were described. It plans to present the full set of data from the study when the Clinical Study Report is ready in June. Based on the lack of detailed data, it is hard to draw conclusions, but based on what was presented, we view this as another setback for the company.
Three Directors at BioArctic AB bought 3,120 shares at between 163.200SEK and 164.700SEK. The significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over th...
According to our tracker, Evolution’s daily average players grew by 10% QOQ in Q1, compared with our quarterly average Live revenue growth of 3% for 2025e. While still early, Q2 has started very strongly, with 12% QOQ player growth so far. In conclusion, our data signals strong underlying demand for Evolution’s products and a vital recovery after the H2 headwinds.
While we acknowledge Nokian Tyres’ ‘local-to-local’ approach in the US may shelter it from worst tariff impacts, we believe increased uncertainty on consumer sentiment in North America could lead to weaker demand for its high-value premium range in the short term, raising the risk of fixed-cost under-absorption and partly offsetting potentially better EBIT drop-through from Romania (Q2 onwards). We reiterate our HOLD, but have cut our target price to EUR6.3 (6.7), following a c9% clean EBIT cut ...
With our unchanged estimates, the well-flagged near-term headwinds and strong player trends confirmed by our tracker, we reiterate our BUY and SEK1,440 target price ahead of the Q1 results (due at 07:30 CET on 30 April). We forecast revenue up 8% YOY and EBITDA of EUR367m (Bloomberg consensus EUR369m). Short-term potential catalysts include the UKGC review conclusions and any signs of revenue growth resilience.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.